

# Daniele Generali

U.O. Multidisciplinare di Patologia Mammaria e  
Ricerca Traslazionale

Azienda Socio-Sanitaria Territoriale di  
Cremona

Dipartimento Universitario Clinico di Scienze  
Mediche, Chirurgiche e della Salute  
Università degli Studi di Trieste



**ENGAGED  
ONCOLOGY WORKFORCE**

**Make a Circle.**

**IN METASTATIC BREAST CANCER**

**Tavola Rotonda:  
Analisi dei dati di Real  
Life ottenuti dall'indagine  
focalizzata sull'esperienza  
del paziente oncologico**

**ENGAGED  
ONCOLOGY WORKFORCE**

**Make a Circle.**

**IN METASTATIC BREAST CANCER**

# Daniele Generali

## Disclosure of potential conflicts of interests

### Consultant:

Novartis, EliLilly, EURAMA

### Honoraria:

EliLilly, Novartis, Pfizer, Roche

### Research Funding from profit organizations:

Asrazeneca, Oncologica LTD

### Funding from non profit organizations:


LILT

### Founder & Chairman:


MEDnoTE S.r.l.



# Cancer Care in the Era of Precision Medicine




Germline  
Variation




Somatic  
Mutation



Personalized  
Care



# New Adaptive Combinations Are More Likely To Deliver Curative Results in the Era of Precision Medicine




Cell 2015 161, 205-214DOI: (10.1016/j.cell.2015.03.030)





# Cancer Care in the Era of Precision Medicine



## Study Respondents:

- Oncologists (307)
- Hospital Pharmacists (428)
- Pharmacologist (277)


**Do you feel informed about Precision Medicine?**

Information needs on precision medicine: a survey of Italian health care professionals.

Addis A, Trotta F, Tafuri G, De Fiore L.

Ann Ist Super Sanita. 2018 Oct-Dec;54(4):316-323

# Cancer Care in the Era of Precision Medicine



Information needs on precision medicine: a survey of Italian health care professionals.

Addis A, Trotta F, Tafuri G, De Fiore L.

Ann Ist Super Sanita. 2018 Oct-Dec;54(4):316-323

# Cancer Care in the Era of Precision Medicine

## The MOzART Program



The **MOzART** Program:

Understanding the **MO**lecular **A**bserrations

**R**elated to Resistance / Responsiveness

To Novel Drugs in Metastatic Solid **T**umors



ENGAGED ONCOLOGY WORKFORCE


**Make a Circle.**

IN METASTATIC BREAST CANCER




# What do patients with advanced breast cancer want to know about their illness and the new treatment options in the Era of Precision Medicine? (The MOzART Program)


Do you want to be informed about your illness?



Do you want to be informed about the new treatment options for ABC?



# Evolving Clinical Management




Provide the optimal trial for a patient rather than find patients for a trial  
**A TRIAL FOR EVERY PATIENT**




ENGAGED ONCOLOGY WORKFORCE  
**Make a Circle.**  
IN METASTATIC BREAST CANCER

# What do patients with advanced breast cancer want to know about new tests, new drugs or new trials? (The MOzART Program)

Do you want to be informed about new tests or news drugs for your ABC?



Do you want to be informed about the new trials with new drugs for your ABC?



# In the Era of Precision Medicine: New Options and/or New Problems

- Patients with a high expectation from new drugs are more likely to choose new treatments with new drugs (without a particular interest in the outcome if known) than conventional therapy
  - FAQ: CDK4/6 Is; Check-Points Is
- Patients who overestimated their chance of survival are likely to receive any kind of life-extending therapy, especially if new trials with new drugs;
  - FAQ: Dr, do you have trial? Dr, Centre with Trials/new Drugs?
- **Pitfall:** The new technologies are inducing high expectations in patients and care-givers and are leading to less effective face-to-face interaction between patients and doctors
  - FAQ: Any tests for my cancer?

